JULY 2018
In an article entitled, “Top 25 Pharma & BioPharma“, ContractPharma reports:
In 2018, Pfizer reported revenues of $53,647 billion, an increase of two percent. Premarin sales delivered $832 million to that total, with sales down -15%. END
OCTOBER 2018
In an article entitled, “Menopausal Hot Flashes Market is Rising to a Valuation of US$ 5,284.1 Mn in 2023,” OnlineNewsGuru.com reports:
Transparency Market Research has published a new market report titled, “Menopausal Hot Flashes Market — Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023.”
According to the report, the global menopausal hot flashes market was valued at US$3.77 bn in 2014 and is projected to expand at a CAGR of 3.7% from 2015 to 2023 to reach US$5.28 bn by 2023.
Hot flashes are the most common vasomotor symptom of menopause complications. The usual symptoms include sudden sensation of intense warmth spreading over body lasting for several minutes leading to sweating, red flush, and palpitations.
Hot flashes may occur during the day or at night (also known as night sweats). The intensity of hot flashes vary from woman to woman depending on several physiochemical factors. It may be mild, moderate and troublesome, or severe and debilitating.
Hormone replacement therapy (HRT) has been considered as gold standard for the treatment of menopausal hot flashes. However, long term HRT has an increased risk of breast cancer and risk associated with increasing age such as stroke, blood clots, and other health related problems.
Other therapies include intake of vitamin E supplements and anti-depressants along with various complementary therapies.
In the U.S. and other developed countries approximately 70% of menopausal women suffer from hot flashes that can last for several years. According to a publication by Harvard Medical School, on average, hot flashes can last for about 7 years to 11 years.
NOVEMBER 2018
In an article entitled, “Pfizer Is Weighing Sale of $2 Billion-Women’s Health Portfolio“, Bloomberg reports:
• U.S. drugmaker is gauging interest from potential buyers
• Suitors likely to include private equity firms and drugmakers
Pfizer Inc. is reviewing options including a sale of its women’s health portfolio as the U.S. pharmaceutical giant seeks to focus on developing treatments with higher growth potential, according to people with knowledge of the matter.
The drugmaker is working with financial advisers to gauge the interest of potential buyers, the people said, asking not to be identified because the deliberations are private. A sale of the division, which has annual sales of roughly $1.2 billion, could fetch about $2 billion and draw bids from both private equity firms and rival pharmaceutical companies, they said.
A spokeswoman for Pfizer said the drugmaker declined to comment on speculation. No final decision has been reached and the company may yet decide to retain the assets, which include menopause treatments such as Premarin, Prempro and Premphase, the people said.
For more on Pfizer’s likely strategy under its new CEO, read this.
A divestment of the business would mean that Pfizer, which last month narrowed its full-year forecast amid manufacturing challenges within the business that makes its older medicines, is joining Allergan Plc and Teva Pharmaceutical Industries Ltd. in selling or winding down women’s health lines and shifting resources to other parts of their portfolios.
Allergan Chief Executive Officer Brent Saunders, who has been seeking to sell the firm’s women’s health and antibiotics divisions, this week said the offers so far have been below what the assets are worth. Last year, Teva opted to sell its women’s health division in separate transactions for about $2.5 billion as it raced to pay down debt. END.
THE HORSES
Premarin, Prempro, Premphase and Duavee are examples of the Premarin family of drugs which are made with the the estrogen rich urine of pregnant mares.
In the ‘pregnant mare urine’ (PMU) industry, horses are repeatedly impregnated so their urine can be collected and made into hormone replacement products . Some of the foals are rescued , but most are simply slaughtered and seen as a byproduct (much like male calves in the dairy industry).
There are alternatives. Talk to your doctor. Visit your local pharmacy. There are prescription free over-the-counter treatments for hot flashes, vaginal dryness and other menopausal symptoms. Thank you.
RELATED READING
Premarin, doctors and conjugated equine estrogens, Tuesday’s Horse, The Horse Fund (Oct. 8, 2018) »
1686-1998 | 2001-2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019
Fund for Horses 